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Abbreviations
PA  Primary aldosteronism
CT  Computed tomography
AVS  Adrenal vein sampling
DDD	 	Defined	daily	dose
APA  Aldosterone-producing adenoma
MRA  Mineralocorticoid receptor antagonist
ADX  Adrenalectomy
Introduction
Primary aldosteronism (PA) represents the most frequent curable 
form of arterial hypertension [1–3]. Its relevant cardiovascular co-
morbidities, with potential reversal or improvement after early di-
agnosis and therapy, justify a screening in high-risk populations 
[4–10]. These include patients with resistant hypertension, spon-
taneous or diuretic-induced hypokalemia, adrenal incidentaloma, 
or sleep apnea [11]. The two major forms of PA are unilateral aldos-
terone-producing adenoma (APA), which is treated by surgery, and 
the more common bilateral adrenal hyperplasia, which is addressed 
by mineralocorticoid receptor antagonist (MRA) treatment [12, 13].
As therapeutic approaches diverge substantially between the two 
subtypes,	differential	diagnosis	is	essential	for	patient	care	[14,	15].	
Following the establishment of the diagnosis of PA, current guide-
lines suggest the performance of adrenal computed tomography 
(CT), which allows to exclude adrenocortical carcinoma as a rare 
cause of aldosterone excess [11, 16]. While CT scans have a high sen-
sitivity in detecting larger adrenal tumors, they only display a limit-
ed	specificity	for	endocrine	active	lesions	due	to	the	high	prevalence	
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ABStr ACt
Adrenal vein sampling (AVS) is considered the gold standard 
for	the	differential	diagnosis	in	patients	with	primary	aldoster-
onism (PA). The distinction between unilateral and bilateral 
disease dictates the targeted therapeutic approach with sur-
gery for aldosterone producing adenomas and medical thera-
py for patients with bilateral hyperplasia. Thereby, this diag-
nostic step is crucial in clinical care. As AVS is an invasive, not 
well standardized procedure that is restricted to few specialized 
centers, several attempts have been made to simplify diagnos-
tic algorithms. In this clinical scenario, the recently published 
SPARTACUS trial aimed at answering the question whether AVS 
in	fact	is	superior	for	differential	diagnosis	in	comparison	to	
imaging of the adrenal glands. In this multicenter study, pa-
tients were randomized to be treated according to AVS results 
or based on abdominal imaging only. Clinical outcome in both 
patient	groups	after	one	year	was	reported	as	not	different.	
While the study results found broad interest, it also stirred con-
siderable controversies. This review provides an overview on 
the	different	views	regarding	the	outline	of	the	SPARTACUS	
trial and the interpretation of its results.
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 d
eg
li S
tu
di
 d
i T
or
in
o.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Beuschlein F et al. Controversies on the SPARTACUS Trial … Horm Metab Res
Review
of adrenal incidentalomas with increasing age [17]. Accordingly, bi-
lateral adrenal vein sampling (AVS) is currently recommended as the 
gold	standard	in	differential	diagnosis	in	PA	patients	willing	to	un-
dergo adrenalectomy (ADX) in case of unilateral disease. The ration-
ale	of	this	procedure	is	to	measure	aldosterone	directly	at	its	off-
spring	in	the	effluents	of	the	adrenal	veins.	A	systematic	review	had	
pointed out a discordance between CT- and AVS-based diagnosis in 
approximately 40 % of the cases [17]. While being safe in experienced 
hands, AVS has been judged as invasive, technically demanding, and 
relatively expensive [18, 19]. In many centers, success rates are low 
[20]. A relevant proportion of patients not treated in specialized 
centers is deprived of this diagnostic tool due to lacking resources. 
Additionally, AVS is not well standardized between centers regard-
ing selectivity and lateralization indices, sequential or simultaneous 
catheterization and the use of cosyntropin, thereby complicating 
comparability	of	diagnosis	findings.	Finally,	it	has	been	criticized,	that	
prospective studies for the reliability of AVS results are lacking. As a 
consequence,	efforts	have	been	made	to	avoid	AVS	at	least	in	some	
patients	based	on	different	algorithms	and	scores	that	had	been	
demonstrated to provide some level of subtype prediction [21–23]. 
Alternative functional imaging techniques including metomidate 
PET-CT	or	the	use	of	specific	aldosterone	synthase	tracer	are	current-
ly	under	investigation	[24,	25].
In this clinical scenario, the SPARCTACUS trial (Subtyping Prima-
ry Aldosteronism: A Randomized Trial Comparing Adrenal Vein 
Sampling and Computed Tomography Scan) recently reported by 
Dekkers and colleagues in the Lancet Diabetes & Endocrinology, 
set out to compare AVS-based and CT-based treatment outcome 
in PA patients [26]. The study reported that treatment decisions 
based on both diagnostic tools led to similar blood pressure im-
provement and health-related quality of life in PA patients at one 
year of follow-up. Therefore, the authors postulated that the ex-
tra-costs of AVS were dispensable and that neither AVS nor CT 
would correctly predict PA subtypes in all cases. Due to its unex-
pected	findings	with	potentially	relevant	and	practical	consequenc-
es for patient care, publication of the study triggered extensive dis-
cussions.	The	current	review	aims	to	outline	the	different	points	of	
view regarding the protocol and the results of the study.
Protocol PRO
The	primary	endpoint	of	the	SPARCTACUS	study	was	defined	as	blood	
pressure control at one year of follow-up [26]. Indeed, the aim to im-
prove clinical outcome represents the real gold standard of diagnos-
tic or therapeutic procedures. As AVS is being criticized to be una-
vailable for the majority of PA patients due to its complexity and re-
striction	to	specialized	centers,	simplified	algorithms	with	improved	
accessibility are required. The implementation of CT scanning in-
stead of AVS, at least in a certain proportion of PA patients, would 
ease the diagnostic work-up in this patient population.
For the completion of this goal, it is important to provide clini-
cal	paths	that	are	based	on	the	best	scientific	evidence,	that	is,	ran-
domized controlled trials. In fact, the SPARTACUS study followed a 
diagnostic, randomized, controlled, multicenter design. PA was 
confirmed	by	accepted	clinical	standards	including	a	salt-loading	
test. The sample size was determined prior to the start of the study 
by power calculations: 200 patients with PA were randomly as-
signed using a web-based algorithm to receive AVS (preceded by 
CT) or only CT to subtype PA. Randomization resulted in a well-bal-
anced distribution of patients between the two groups. Patients 
randomized to CT were adrenalectomized in case of a unilaterally 
enlarged adrenal gland and a normal appearing contralateral gland. 
In contrast, patients with normal or bilaterally enlarged adrenal 
glands were treated with mineralocorticoid antagonists. For bet-
ter comparison, adrenal CT was assessed by a local radiologist and 
reviewed by a central facility. In cases of discrepancy between these 
CT	readings,	the	final	decision	was	taken	by	the	local	center.
AVS performance is variable across centers in term of procedure 
and interpretation [27, 28]. In the SPARTACUS study, AVS was per-
formed according to accepted protocols under continuous cosyn-
tropin stimulation with sequential catheterization of the adrenal 
veins. Based on a selectivity index of 3.0 or higher, the success rate 
for bilateral cannulation of the adrenal veins was reported as high as 
96 %. Patients with unilateral disease (based on a lateralization index 
of 4.0 or higher and a suppression index of 1.0 or lower) were adre-
nalectomized. In cases of bilateral disease, mineralocorticoid antag-
onist treatment was initiated. In those instances when AVS failed, 
patients	were	treated	according	to	CT	findings.	Thereby,	the	applied	
criteria for the interpretation can be regarded as strict enough to en-
sure rigorous diagnosis. In two large studies, ACTH stimulation re-
sulted	in	1–4/46	difference	in	diagnosis	compared	with	unstimulat-
ed procedures [29, 30]. Therefore, it is highly improbable that this 
could	have	an	impact	on	the	final	outcome	of	the	study.
From initially 200 enrolled patients, 184 completed follow-up 
with even distribution in the AVS and CT group. Patients were in-
vestigated according to an intention-to-diagnose analysis for the 
primary endpoint at 12 months following therapy. In fact, this in-
terval has recently been endorsed by an international expert panel 
as a relevant time point for re-assessment of clinical outcome in PA 
patients [31]. As a measure of blood pressure control, the intensi-
ty of antihypertensive treatment for obtaining target blood pres-
sure 	 ( 	< 	135/85	mmHg	 us ing	 a 	 semiautomatic 	 dev ice	
or		<	140/90	mmHg	using	office	measurement)	was	quantified	as	
defined	daily	dose	(DDD).	This	approach	represents	a	practical	end-
point, as blood pressure is the parameter relevant for the patients 
[32]. Ambulatory blood pressure was used, which is a very objec-
tive form of monitoring. Key secondary endpoints were biochem-
ical outcome in patients who had undergone ADX, which was ana-
lyzed by salt-loading test. Further endpoints included physical and 
mental scores, the proportion of patients reaching target blood 
pressure,	adverse	events,	and	cost-effectiveness.	The	latter	point	
is of great importance, as AVS is relatively expensive, which might 
not	be	justified	if	it	would	lack	diagnostic	superiority.
In	summary,	patients	were	scrutinized	by	a	well-defined	clinical	
protocol, allocated into diagnostic procedure groups in a rand-
omized fashion and prospectively followed up. In this regard, the 
SPARTACUS trial has implemented the highest standards of a clin-
ical	study	design.	To	this	point,	it	is	the	first	and	only	in	the	field	of	
clinical PA research that aims at this evidence level.
Protocol CONTRA
The SPARTACUS trial randomized 184 subjects with PA to adrenal CT 
scanning	or	adrenal	CT	scanning	plus	AVS	to	establish	the	final	sub-
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type diagnosis and address the patients with a unilateral disease to 
surgery [26]. The authors should be commended for the perfor-
mance	of	the	first	randomized	trial	on	this	disease,	however	the	de-
sign of the SPARTACUS study has some weak points that could re-
duce the relevance of the results and their application in clinical prac-
tice. The most important points are: 1) DDD is not the appropriate 
primary end-point for this type of study; 2) the SPARTACUS cohort 
is not representative of the general PA population and therefore the 
results cannot be generalized; 3) the comparison between AVS ver-
sus CT-based MRA therapy was not necessary and reduced the power 
of the study; 4) the sample size of the investigated population was 
not adequate to prove the non-inferiority of CT scanning in compar-
ison with AVS to determine indication for ADX.
The	first	consideration	is	that	DDD	is	not	the	appropriate	prima-
ry end-point. First, it does not evaluate the biochemical cure of PA, 
the most reliable measure of the success of ADX [31]; second, it 
does not take into account the concomitant presence of essential 
hypertension	that	can	confound	the	final	outcome	judgment;	fur-
ther, the intensity of the treatment depends largely on the type of 
drug that is considered in the calculation. As an example, a patient 
with blood pressure levels of 130/80 mmHg before ADX under 
spironolactone	75	mg,	amlodipine	5	mg,	lisinopril	10	mg,	and	hy-
drochlorothiazide	12.5	mg	has	a	DDD	=	3.5;	the	same	patient,	with	
the same blood pressure after ADX, taking ramipril 10 mg as mon-
otherapy,	has	a	DDD	=	4.	Clinicians	would	unanimously	consider	
this patient largely improved and not worsened as it appears if the 
DDD is used as an indicator of clinical success after unilateral ADX.
The second consideration is that the SPARTACUS cohort is not 
representative of the general PA population and, therefore, the re-
sults cannot be generalized. Criteria for inclusion were: hyperten-
sion requiring 3 or more antihypertensive drugs in adequate doses 
and/or hypertension accompanied by spontaneous or diuretic-in-
duced	hypokalemia	(serum	potassium		<	3.5	mmol/l),	which	means	
that only patients with a severe phenotype of PA were selected. In 
the recent PATO (primary aldosteronism in Torino) study, per-
formed on the general hypertensive population seen in primary 
care practice, the majority of PA patients would not have been in-
cluded in the SPARTACUS trial because of a milder phenotype [33]. 
For	example,	in	the	PATO	study,	APA	accounted	for	25	%	of	all	PA	
cases,	whereas	in	the	SPARTACUS	their	prevalence	was	50	%;	fur-
thermore, hypokalemia was observed in 29 % of the patients with 
PA in the PATO study versus 68 % in the SPARTACUS cohort. The data 
of the PATO study are also coherent with a retrospective evaluation 
of the clinical and biochemical features of patients with PA in refer-
ral	centers	from	five	continents	[2].	It	is	conceivable	that	patients	
with a severe PA phenotype and high prevalence of APA will respond 
to ADX (even if AVS is not performed), but this would not be the 
case for patients with a mild form of the disease.
Another	major	flaw	of	the	design	of	the	study	is	the	choice	of	
randomizing patients to CT-based MRA therapy and AVS-based 
MRA therapy [26]. It is in fact well known, since the publication of 
the studies performed by the Cleveland Clinic group, that patients 
with APA respond well to MRA [34]. Similarly, a more recent study 
demonstrated that adequate doses of spironolactone determine a 
blood	pressure	reduction	similar	to	that	obtained	with	ADX	[35].	
Therefore, this arm of the study reduces the power of the other 
comparison, without providing any useful novel information.
In a systematic review/meta-analysis, Kempers et al. showed 
that	AVS	and	CT	scanning	result	in	a	different	diagnosis	in	around	
38 % of cases [17]. In 19 % of cases, patients would have been inap-
propriately excluded from ADX following CT scanning, where AVS 
showed unilateral secretion; however, this discrepancy would not 
affect	the	results	of	the	SPARTACUS	study.	Therefore,	only	18.5	%	
of patients (14.6 % having an inappropriate ADX when AVS showed 
a bilateral disease plus 3.9 % having ADX on the wrong side when 
AVS showed aldosterone secretion on the opposite side) would be 
inappropriately adrenalectomized following CT scanning instead 
of	AVS.	It	should	be	emphasized	that	ADX	is	also	effective	in	some	
selected patients with bilateral PA: in fact, it resulted in hyperten-
sion	cure	in	15	%	of	cases	and	improvement	in	another	20	%	[36].	
Based on this assumption, no more than 6 to 9 patients are expect-
ed to have persistence of PA if a cohort of 46 patients is adrenalec-
tomized following CT scanning alone; interestingly, the persistence 
of PA in the SPARTACUS study is 9/46.
In the primary aldosteronism surgery outcome (PASO) study, 
AVS resulted in a complete biochemical cure of PA in 94 % of the 
patients [31]. Using the expected rate of cure of ADX following the 
indication	of	CT	scanning	versus	AVS,	a	number	of	258	patients	
would have been necessary instead of 46, to prove the non-inferi-
ority of CT scanning with respect to AVS for the diagnosis of unilat-
eral PA.
In conclusion, the SPARTACUS trial conveys the strong message 
that in patients with PA ADX based on CT diagnosis has a similar 
outcome	compared	with	ADX	based	on	AVS	findings,	thereby	chal-
lenging the current Endocrine Society Guideline [11]. However, the 
above	discussed	pitfalls	significantly	affected	the	results	and	limit-
ed its generalizability to the whole PA population.
Results PRO
Although the clinical, cardiac, and renal outcomes of PA have been 
shown to be comparable in patients treated with ADX or MRA [37], 
differentiation	between	unilateral	or	bilateral	forms	of	this	condi-
tion	is	still	widely	considered	to	be	essential	for	definition	of	the	ap-
propriate	therapeutic	choice	[11].	To	this	purpose,	different	ap-
proaches have been used in the past, including CT or MRI-based 
imaging, adrenal scintigraphy, metomidate PET-CT, and AVS. Pre-
vious retrospective investigations pointed out a substantial dis-
cordance	(more	than	40	%)	between	AVS	and	CT	in	differentiation	
of unilateral from bilateral adrenal disease in PA [17]. Because of 
the functional information provided by AVS, this was indicated as 
the	“gold	standard”	for	differentiation,	thereby	generating	the	pre-
conception that AVS is almost always right, whereas CT is frequent-
ly wrong. As a consequence, AVS has been asserted as the unavoid-
able cross road in the diagnostic workup recommended to the ma-
jority of patients with PA [11]. However, no demonstration of this 
alleged superiority of AVS over other diagnostic methods for char-
acterization of unilateral or bilateral forms of PA could be found in 
the medical literature and until the publication of the SPARTACUS 
study [26] no prospective assessment of this issue had been done. 
As already stated, randomized controlled trials provide the best 
clinical evidence for clinical decisions and the SPARTACUS trial was 
the	first	of	this	kind.	The	study	compared	the	outcome	of	CT-based	
management with AVS-based management in an appropriately 
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sized sample of patients with PA who were treated with either ADX 
or MRA and were followed for one year. The outcome was assessed 
in a intention-to-diagnose analysis and both in primary (DDD and 
number of antihypertensive drugs used at follow-up) and most of 
secondary endpoints (proportion of patients reaching target blood 
pressure; serum potassium; plasma aldosterone levels after 
salt-loading post-ADX; patients with biochemical evidence of re-
solved PA; health-related quality of life, physical and mental; ad-
verse	events)	no	significant	differences	were	observed.	The	only	
difference	was	found	in	the	mean	total	cost	of	the	procedure	per	
patient that was 60 % higher in those patients who underwent AVS. 
Notably,	primary	and	secondary	endpoints	did	not	differ	between	
the CT and AVS group even when patients who were treated with 
surgery or MRA were analyzed separately.
Although	some	reasonable	and	also	some	definitely	questiona-
ble critiques have been raised to the SPARTACUS study, it cannot 
be denied that this is the only study that has approached the issue 
of the validity of AVS in a prospective randomized protocol, provid-
ing	a	clear	demonstration	that	if	CT	is	not	foolproof	for	differenti-
ation of unilateral from bilateral forms of PA, AVS is no better. These 
conclusions wipe out the misconception that AVS could be consid-
ered	a	gold	standard	for	definition	of	subtypes	of	PA	and	undermine	
the Manichaean view that many have of it.
The results of the SPARTACUS study should not get to surprise 
because data on AVS previously obtained in the top referral centers 
performing AVS worldwide had already pointed out at its serious 
limitations. In the German’s Conn registry the results of 200 AVS 
procedures were analyzed in two phases, retrospective and pro-
spective, after introduction of measures designed to improve the 
rates of successful cannulation. The rate of success in correct col-
lection of adrenal samples was less than one third in the retrospec-
tive phase and less than two thirds in the prospective phase [20]. 
Also, the rate of success was extremely variable, from 80 % to less 
than 30 %, depending upon the stringency of the selectivity index 
that	had	been	used.	Similar	findings	were	reported	in	Turin	where	
the results of AVS in 64 patients with PA who had undergone the 
procedure	twice	showed	an	impressive	disparity	in	the	definition	
of successful cannulation of adrenal veins and lateralized aldoster-
one secretion depending upon the stringency of the criteria that 
were used [38]. In this study, the rate of concordance among three 
different	criteria	used	for	definition	of	lateralized	secretion	was	32	%	
and the rate of concordance between the two procedures per-
formed	in	the	same	patient	was	35	%.	To	notice,	lateralization	as	
detected by AVS changed from unilateral in one side to unilateral 
in	the	contralateral	side	in	14	%	of	patients.	In	Paris,	more	than	500	
AVS	were	retrospectively	reviewed	comparing	the	different	diag-
nostic criteria used in 4 of the top referral labs for AVS [39]. Com-
parison between the lab that used the most stringent criteria with 
the	lab	that	used	the	most	lenient	showed	a	five-fold	difference	in	
the proportion of unsuccessful procedures (18 % vs. 4 %) and a two-
fold	difference	in	the	proportion	of	lateralized	aldosterone	secre-
tion (26 % vs. 60 %). Because of the lack of standardization of AVS 
among referral centers consensus documents have been published 
by expert committees [27, 28], but if one looks carefully at them 
many	substantial	differences	still	can	be	found	showing	that	there	
is very little consensus even among experts. Thus, while being rel-
atively safe in experienced hands, the procedure of AVS is invasive, 
technically demanding, relatively expensive, and inadequately 
standardized	and,	in	the	light	of	the	findings	of	the	SPARTACUS	
study,	does	not	seem	to	offer	any	advantage	over	CT	in	the	out-
come of patients treated for PA.
In	summary,	the	findings	of	the	SPARTACUS	study	strongly	sup-
port	the	concept	that	AVS	is	not	a	gold	standard	for	differentiation	
of	PA	subtypes	and	keep	wide	open	the	possibility	to	define	the	op-
portunity for unilateral ADX or, alternatively, MRA treatment with 
diagnostic approaches, such as CT, that have a comparable level of 
reliability. Needless to say, this should be always done under the 
guidance of a balanced clinical judgment that takes into account 
all	information	on	each	single	patients	that	is	the	first	ingredient,	
beyond and above guidelines, for taking appropriate clinical deci-
sions.
Results CONTRA
The investigators for the SPARTACUS Trial are to be congratulated 
for	completing	the	first	prospective	study	comparing	CT-	versus	
AVS-guided treatment of patients with PA, an impressive achieve-
ment given the large amount of planning, workload and funding 
support that would have been required. However, careful exami-
nation	of	the	results	reveals	a	number	of	anomalous	findings	that	
raise serious concerns about the validity and generalizability of the 
data and the conclusions that have been drawn. Furthermore, there 
are clear trends towards superiority of AVS that add weight to the 
argument	provided	above	that	the	power	of	the	study	was	insuffi-
cient	to	show	significant	differences	between	the	two	study	groups	
in terms of treatment (and in particular, ADX) outcomes.
There	are	a	number	“odd”	findings	in	SPARTACUS:
(1)  The rate of lateralization in the CT and AVS groups was 
exactly	the	same	at	50	%,	which	is	in	sharp	contradiction	to	
the reports of previous studies in which centers relying on 
CT-based	subtype	differentiation	found	much	lower	rates	of	
detection of APA than those employing AVS [2]. One 
potential explanation for this is the very permissive criteria 
used for lateralization on CT, requiring only an enlargement 
(not	even	a	mass	lesion)	of	an	adrenal,	defined	as	a	thickness	
of 7 mm or more in the body or limb. Surely the investigators 
are not suggesting that, with all we have learned through 
countless previous studies about the unreliability of even a 
mass	lesion	on	CT,	this	is	sufficient	to	warrant	proceeding	to	
surgery without any other supporting evidence of lateraliza-
tion whatsoever? Another possible explanation for this 
anomalous result is selection bias towards subjects with 
more	florid	(and	hence	more	likely	unilateral)	varieties	of	PA,	
leading to an over-representation of patients with larger 
APAs more easily detectable by CT, which is supported by 
other lines of evidence outlined below.
(2)	 	A	50	%	rate	of	lateralization	is	high	even	for	AVS-based	
subtype	differentiation	when	compared	with	most	other	
recent reports [2, 40] with the exception of some Asian 
cohorts [41, 42], and centers which use very permissive 
lateralization criteria [38, 43] (which the SPARTACUS 
investigators did not). This again suggests selection bias.
(3)  Moreover, the high proportion of hypokalemic patients 
( > 60 %, where most other studies report hypokalemia in the 
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minority) among the SPARTACUS cohort is further evidence 
for selection of more severe, advanced PA, which may have 
been easier to localize by CT.
(4)  Whereas most PA cohorts show a roughly equal gender 
distribution, in SPARTACUS, males made up over three-quar-
ters of PA patients. This inexplicable result again hinders 
generalization	of	SPARTACUS	findings	to	other	centers.
(5)	 	There	was	a	much	higher	localization	of	“APA”	to	the	left	
(76 % vs. right 24 %) in the CT group compared to the AVS 
group	(54	vs.	46	%)	and	to	PA	cohorts	in	other	studies.	This	
may, at least in part, be due to nearby splenic vessels which 
can be mistaken for APAs. Whatever the reason, it does not 
bode well for the validity of CT lateralization.
(6)	 	The	overall	very	low	rate	of	HT	cure	(14	of	92	=	15	%)	among	
the ADX patients is also unexplained. This mirrors the 
relatively poor outcomes of the same Netherlands and Polish 
centers that contributed to the recently reported PASO study 
when compared with almost every other center that 
participated [31]. Not only does this raise further concerns 
about generalizability, but it also would have seriously 
impacted	on	the	power	of	the	study	to	show	differences	in	
cure rates between the CT- and AVS-based treatment groups 
(see below).
(7)  Given that the real “proof of the pudding” in terms of 
attempts at lateralization is in the response to ADX, it is 
uncertain why the investigators even bothered to look at 
responses	to	MRA.	But	even	there,	the	surprising	finding	that	
non-lateralizing patients in the AVS group need more DDDs 
than	those	in	the	CT	group	(median	5.7	vs.	4.0;	p	=	0.05)	
defies	logical	explanation	and	casts	doubt	on	the	effective-
ness of randomization.
Notwithstanding	the	many	anomalous	findings	and	concerns	
about selection bias and generalizability raised above, there were 
still	several	important	findings	in	SPARTACUS	that	argued	against	
a CT-based approach but which were largely left unmentioned by 
the authors:
(1)  In the CT-based treatment group, consensus could not be 
reached regarding lateralization in a sizable proportion of 
patients (11 of 98), almost all of whom were assigned to 
MRA, whereas AVS was unsuccessful in permitting a 
diagnosis in only four of 96.
(2)	 	In	keeping	with	an	enormous	body	of	existing	data,	a	full	50	%	
of the 90 patients from the AVS group who had both 
conclusive CT and AVS demonstrated discordant results 
between the two procedures.
(3)  Most importantly, despite the very low hypertension cure 
rate observed following ADX, there was still a strong trend 
towards a superior cure rate among the AVS-based treat-
ment group (22 %) compared with the CT group (9 %) which 
almost	reached	statistical	significance	(p	=	0.08).	Had	the	
study been powered to examine this (rather than DDDs) as 
the primary endpoint, as has been recommended by the 
PASO	investigators	[31],	it	is	highly	likely	that	a	significant	
difference	would	have	been	observed.	As	it	is,	with	such	a	low	
overall rate of hypertension cure, SPARTACUS was clearly 
seriously underpowered.
(4)  Biochemical responses to ADX also tended towards superior 
outcomes for the AVS group, with persistent PA being 
observed in almost double the operated patients in the CT 
group compared with the AVS group (20 vs. 11 %), but again 
with	numbers	too	small	to	reach	statistical	significance.
In short, SPARTACUS results are non-generalizable and the study 
was powered to the wrong primary endpoint (rather than more 
meaningful ones such as cure of hypertension and PA in response 
to ADX). Despite this, the trends for superiority of AVS were clear-
ly there but unfortunately ignored.
Even	if	we	give	SPARTACUS	the	benefit	of	the	doubt	and	accept	
that removing the wrong gland, or inappropriately removing a 
gland from a patient with non-lateralizing PA, occurs in only a mi-
nority of patients in whom management is guided by CT (and was 
therefore not detectable in this underpowered, cohort-based 
study), such undesirable outcomes should be avoided wherever 
possible.
Conclusions
SPARTACUS has attempted to address an important clinical ques-
tion in comparing AVS- with CT-based decision making in terms of 
the	outcome	of	surgical	and	specific	medical	treatment	in	patients	
with PA. Its strengths include its robust protocol, the fact that it is 
the	first	randomized,	prospective	study	in	its	field,	the	relatively	
strict criteria used to determine lateralization of aldosterone pro-
duction on AVS, and the use of 24-h ambulatory blood pressure 
monitoring to assess blood pressure outcomes. However, there are 
also	significant	limitations,	the	most	concerning	of	which	are	evi-
dence of selection bias, anomalous results, the unusual choice of 
primary endpoint (DDDs), the decision to include responses to 
MRAs,	and	the	low	power	of	the	study	to	show	difference	in	more	
traditional endpoints (particularly cure of hypertension post ADX). 
Hence, while both CT and AVS are clearly imperfect in predicting 
responses to PA treatment, it remains debatable as to whether 
SPARTACUS	has	managed	to	definitively	refute	the	long	held	view	
that AVS is still best.
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